Table 4 |
|||
|
Change in Outcome Measures after 8 weeks (For subjects with at least 80% compliance) (n = 27-37) |
|||
|
Variable |
Blend 1 (mean ± SD) |
Blend 2 (mean ± SD) |
Placebo (mean ± SD) |
|
|
|||
|
Endothelial Function |
|||
|
Flow-mediated dilatation, % |
0.60 ± 4.30 |
1.00 ± 3.401 |
0.60 ± 4.20 |
|
Stimulus-adjusted response measure |
-0.04 ± 0.33 |
-0.04 ± 0.28 |
-0.05 ± 0.28 |
|
Serum Measures |
|||
|
Insulin, pmol/L |
65.28 ± 362.53 |
-29.17 ± 232.66 |
20.14 ± 225.71 |
|
Fasting plasma glucose, mmol/L |
0.16 ± 1.75 |
0.11 ± 1.69 |
0.07 ± 1.61 |
|
Anthropometric Measures |
|||
|
Body Weight, kg |
0.90 ± 2.90 |
0.20 ± 2.50 |
0.40 ± 2.00 |
|
Body Mass Index, kg/m2 |
0.30 ± 0.90 |
0.00 ± 0.80 |
0.10 ± 0.70 |
|
Lipid Panel |
|||
|
Total Cholesterol, mmol/L |
0.10 ± 0.62 |
0.04 ± 0.49 |
0.01 ± 0.62 |
|
High Density Lipoprotein (HDL), mmol/L |
0.04 ± 0.21 |
0.06 ± 0.15 |
0.10 ± 0.17 |
|
Total Cholesterol/HDL |
-0.10 ± 0.70 |
0.00 ± 0.801 |
-0.40 ± 0.80 |
|
Triglycerides, mmol/L |
0.03 ± 0.71 |
0.24 ± 0.60 |
-0.19 ± 0.87 |
|
Low Density Lipoprotein (LDL), mmol/L |
-0.04 ± 0.71 |
0.11 ± 0.55 |
-0.01 ± 0.74 |
|
|
|||
|
1 p = 0.02 as compared to placebo; |
|||
|
Ali et al. Nutrition Journal 2011 10:72 doi:10.1186/1475-2891-10-72 |
|||
